

kkc & associates llp

Chartered Accountants

(formerly Khimji Kunverji & Co LLP)

Independent Auditor's Review Report on unaudited financial results for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 of Blue Jet Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Blue Jet Healthcare Limited

Introduction

1. We have reviewed the accompanying statement of unaudited financial results of Blue Jet Healthcare Limited ('the Company') for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Interim Financial Reporting' specified in section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Scope of Review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India ('the ICAI'). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **KKC & Associates LLP**

Chartered Accountants

(formerly Khimji Kunverji & Co LLP)

Firm Registration Number: 105146W/W100621



Kamlesh R Jagetia

Partner

ICAI Membership No: 139585

UDIN: 25139585BMQWAG1372



Place: Navi Mumbai

Date: 29 January 2025

BLUE JET HEALTHCARE LIMITED
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THREE MONTHS AND NINE MONTHS ENDED 31-12-2024


₹ in million

Particulars	Three Months Ended			Nine Months Ended		Year Ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from Operations	3,183.82	2,082.60	1,667.60	6,895.40	5,276.53	7,115.98
2 Other Income	132.41	120.74	67.54	340.31	200.31	288.60
3 Total Income (1+2)	3,316.23	2,203.34	1,735.14	7,235.71	5,476.84	7,404.58
4 Expenses						
Cost of Materials Consumed	1,712.44	1,146.25	671.89	3,767.64	2,456.76	3,042.68
Changes [Decrease/(Increase)] in Inventories of Finished goods and Work-in-Progress	(268.24)	(251.10)	36.62	(690.16)	(172.58)	101.33
Employee Benefits Expense	148.25	153.99	130.21	450.05	390.63	531.85
Finance Costs	0.16	0.21	0.37	0.64	1.28	1.61
Depreciation and Amortisation Expense	47.45	46.15	78.55	128.42	203.72	280.91
Other Expenses	351.23	338.60	283.06	990.24	840.10	1,147.82
Total Expenses	1,991.29	1,434.10	1,200.70	4,646.83	3,719.91	5,106.20
5 Profit before exceptional items and tax (3-4)	1,324.94	769.24	534.44	2,588.88	1,756.93	2,298.38
6 Exceptional Items (Refer Note 3)	-	-	(97.43)	-	(97.43)	(97.43)
7 Profit before Tax (5-6)	1,324.94	769.24	437.01	2,588.88	1,659.50	2,200.95
8 Tax Expense:						
Current Tax	325.00	177.50	126.00	600.00	424.50	542.00
Deferred Tax	10.11	8.25	(10.08)	37.78	(6.02)	21.44
Total Tax Expense	335.11	185.75	115.92	637.78	418.48	563.44
9 Profit for the period/ year (7-8)	989.83	583.49	321.09	1,951.10	1,241.02	1,637.51
10 Other Comprehensive Income						
Items that will not be reclassified to profit or loss	-	-	-	-	1.96	(0.19)
Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	(0.49)	0.05
Other Comprehensive Income for the period/ year	-	-	-	-	1.47	(0.14)
11 Total Comprehensive Income for the period/ year (9 + 10)	989.83	583.49	321.09	1,951.10	1,242.49	1,637.37
12 Paid-up Equity Share Capital (Face Value ₹ 2 per share)	346.93	346.93	346.93	346.93	346.93	346.93
13 Other Equity						8,105.30
14 Earnings per Share (EPS) of Face value ₹ 2/- each*						
(a) Basic - (₹)	5.71	3.36	1.85	11.25	7.15	9.44
(b) Diluted - (₹)	5.71	3.36	1.85	11.25	7.15	9.44
*EPS are not annualised for interim periods						

Notes:

- The above financial results of the Company for the three months and nine months ended December 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 29, 2025. Further, the above financial results have been reviewed by the Statutory Auditor of the Company.
- The company is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products.
- During the previous year, an incident at the Mahad facility resulted in a loss of damaged assets and compensation to employees aggregating to ₹ 97.43 million, accounted for as an exceptional items by the company.
- During the nine months ended December 31, 2024, the Company changed its method of depreciation from the Written Down Value (WDV) to the Straight-Line Method (SLM) based on the assessment of technical parameters of the said property plant & equipment, which indicates a more uniform consumption of economic benefits over time. Consequently, for the nine months ended December 31, 2024 and three months ended December 31, 2024 the depreciation expense is lower by and profit before tax is higher by ₹ 108.48 million and ₹ 36.79 million respectively.
- The Company does not have any subsidiaries, associates, or joint ventures as on December 31, 2024. Consequently, the preparation of consolidated financial statements is not applicable.

Navi Mumbai
Date: January 29, 2025



For and on behalf of Board of Directors

Shiven Anora
Shiven Anora
Managing Director



- A. Statement On Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. – **Not Applicable**
- B. Format For Disclosing Outstanding Default on Loans and Debt Securities – **Not Applicable, No Borrowings**
- C. Format For Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – **Not Applicable**
- D. Statement On Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along with Annual Audited Financial Results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - **Not Applicable**